MLEC — Stock Film
STOCK FILMSCENE 1/10MLEC · $7.39
Stock Expert AI presents
MLEC
Moolec Science SA
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Moolec Science SA. What it actually does.

Produce animal proteins in plants using Molecular Farming technology. Develop sustainable and efficient methods for protein production. Now — the numbers.

$5.4M market value
Revenue last year:
$333.6M
The loss that same year:
$111.5M
For every $1 it earns, the company spends $1.3.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$9M
DEBT: $246.9M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
41
weak

Clearly below the class average.

FINANCIAL STRENGTH
29
very weak

Clearly below the class average.

VALUATION
12
very weak

Clearly below the class average.

GROWTH
50
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
23
very weak

Clearly below the class average.

WORTH WATCHING

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Sales are growing fast10/10
WEAK SPOTS
The stock has lost its spark0/10
Little set aside for the future2/10
Thin trading in the shares3/10
WORTH WATCHING

R&D Investment: Spending on future research is low.

THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/1
The product is selling

Sales run at $333.6M a year. A small number, but proof the product has real buyers.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $111.5M against $333.6M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
24 / 100 · MoonshotScore

On our five-subject report card, MLEC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: MLEC is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (12/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →

Not covered, because the filings we hold do not carry it: the revenue breakdown.

This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film